Skip to content


  • Nano Express
  • Open Access

Passage of Magnetic Tat-Conjugated Fe3O4@SiO2 Nanoparticles Across In Vitro Blood-Brain Barrier

Nanoscale Research Letters201611:451

  • Received: 14 September 2016
  • Accepted: 5 October 2016
  • Published:


Delivery of diagnostic or therapeutic agents across the blood-brain barrier (BBB) remains a major challenge of brain disease treatment. Magnetic nanoparticles are actively being developed as drug carriers due to magnetic targeting and subsequently reduced off-target effects. In this paper, we developed a magnetic SiO2@Fe3O4 nanoparticle-based carrier bound to cell-penetrating peptide Tat (SiO2@Fe3O4 -Tat) and studied its fates in accessing BBB. SiO2@Fe3O4-Tat nanoparticles (NPs) exhibited suitable magnetism and good biocompatibility. NPs adding to the apical chamber of in vitro BBB model were found in the U251 glioma cells co-cultured at the bottom of the Transwell, indicating that particles passed through the barrier and taken up by glioma cells. Moreover, the synergistic effects of Tat and magnetic field could promote the efficient cellular internalization and the permeability across the barrier. Besides, functionalization with Tat peptide allowed particles to locate into the nucleus of U251 cells than the non-conjugated NPs. These results suggest that SiO2@Fe3O4-Tat NPs could penetrate the BBB through the transcytosis of brain endothelial cells and magnetically mediated dragging. Therefore, SiO2@Fe3O4-Tat NPs could be exploited as a potential drug delivery system for chemotherapy and gene therapy of brain disease.


  • Blood-brain barrier
  • Magnetic nanoparticles
  • hCMEC/D3 cell
  • Magnetic targeting
  • Tat peptide


The blood-brain barrier (BBB) comprised of brain capillary endothelial cells is the most restrictive barrier in vivo that hampers the transport of s ubstances from the peripheral circulation to the brain and helps maintain brain homeostasis [1]. However, essentially 98 % of small-molecule drugs and 100 % of large-molecule drugs do not pass through the physiologic barrier that inhibit drug delivery from blood circulation to brain tissue [2, 3]. Therefore, the development of a novel drug delivery system to aid drugs across the BBB is the crucial point of the treatment of many brain diseases.

Currently, different strategies for bypassing the BBB have been developed, including direct injection into the brain, transient disruption of the BBB, inhibition of efflux pumps, pro-drug strategy, and receptor-mediated transcytosis [48]. Nanoparticle-based delivery system has been proved an advantage in effective transportation of various drugs across BBB [911], especially iron oxide nanoparticles (IONPs) have attracted significant importance in the last decade due to their intrinsic magnetophoretic mobility, which enable targeting the lesions by magnetic guidance and reducing off-target effects [12]. Because of high surface-to-volume and the magnetic interaction, bare IONPs tended to aggregate and lower magnetic responds by oxidation, which induce a limited drug targeting [13]. Several biocompatible polymers, such as PEG, chitosan, alginate, dextran, and fetal calf serum, have been used to stabilize Fe3O4 particles and further functionalize [1416]. Among all the possible surface modifications for IONPs, silica (SiO2) coating was supposed especially suitable to be employed for medical purposes due to high pore volume, good biocompatibility, and its transparency [17, 18]. It has been proved that silica coating on IONPs improves cellular uptake and achieves targeted delivery of drug under magnetic field condition [19, 20]. However, low efficiency of permeability and accumulation in the brain is still a great issue.

Cationic cell-penetrating peptides (CPPs) can facilitate the internalization of attached macromolecules and even nano-carriers (e.g., polymers, liposomes) by various cells via independent transporters and receptor-mediated endocytosis [21, 22]. A number of CPPs including trans-activating transcriptional activator (TAT), angiopep, penetratin, rabies virus glycoprotein (RVG), prion peptide, and SynB have already been demonstrated the ability of improving drug delivery across the BBB [23, 24]. Peptide Tat (YGRKKRRQRRR), derived from TAT protein, can increase the permeability of brain endothelial cells by inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9 [25]. It has been demonstrated that Tat-conjugated nanoparticles can deliver siRNA and drug across the BBB to kill intracerebral malignant glioma cells and further extend the mouse life span [26]. On the other hand, the permeation mechanism and the precise location of the particles across the BBB remain poorly understood at a cellular level [27]. In vitro BBB model may keep the status of BBB integrity, which helps to be understood in terms of how BBB facilitate or interfere with drug delivery [28].

In the present study, we developed a novel core-shell structured magnetic Tat-conjugated SiO2@Fe3O4 nanoparticles (NPs). This study aimed to evaluate the nanoparticles’ permeability across BBB and their fates in accessing BBB as shown in Scheme 1. Human brain endothelial cell (hCMEC) monolayer and hCMEC/U251 co-culture model were used to examine cellular uptake, BBB permeability, and subsequently location in U251 cells in the absence and presence of a magnetic field. Besides, the physicochemical properties, cytotoxicity, and the integrity of monolayer were also investigated. The studies of systematic effect of cell-penetrating peptide and magnetic field on mediating BBB permeability and internalization into brain endothelial cells may aid to design peptide-functionalized magnetic NPs for brain targeting in the future.
Scheme 1
Scheme 1

Design and synthesis of Fe3O4@SiO2-Tat magnetic NPs to enhance the permeability across the BBB


Materials and Cell Lines

Tetraethyl orthosilicate (TEOS), ferrous chloride (FeCl3), ferric chloride (FeCl2), and sodium citrate were purchased from Xilong Chemical Co., Ltd. (Shantou, China). 3-Aminopropyl-trimethoxysilane (APTMS) was purchased from Acros Organics (Belgium, USA).

N-Hydroxy sulfo-succinimide (NHS), 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride (EDC), and FITC-labeled Tat (Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg) peptide were provided by Gier Biochemistry Co., Ltd. (Shanghai, China). BCA protein assay kit was purchased from Applygen Technologies Inc. (Beijing, China). External magnetic field was applied by placing an Nd–Fe–B magnet under the culture plates using an immobilized tube apparatus. Human glioma cell lines U251 and human brain capillary endothelial cells hCMEC/D3 (abbreviated as hCMEC) were purchased from BeNa Culture Collection (Beijing, China). All the cells were cultured in RPMI-1640 media with 10 % fetal bovine serum, 10 % penicillin, and 10 % streptomycin at 37 °C in CO2 incubator.

Synthesis of Tat-SiO2@Fe3O4 NPs

The magnetic Tat-SiO2@Fe3O4 NPs were synthesized as the following steps. The superparamagnetic Fe3O4 NPs were synthesized firstly by alkaline co-precipitation [29]. Under vigorous stirring at 80 °C, ammonia water was dropped into the mixture solution of Fe(II) and Fe(III) (molar ratio = 2:1) till the pH 10. After 20 min of continued stirring, sodium citrate (Na3Cit) was added into the mixture at 40 °C with stirring for 90 min under N2 protection to obtain black magnetite Fe3O4 NPs. Secondly, SiO2-coated Fe3O4 NPs (SiO2@Fe3O4 NPs) were prepared by the Stöber method [30]. The as-prepared 10 mg of Fe3O4 NPs was ultrasonically dispersed into a mixture of ethanol/water solution (50.7 mL; v:v, 50:0.7), TEOS(0.3 mL), and NH4OH (1.7 mL) and then continuously stirred for 3 h. The obtained NPs were collected using an external magnet and washed sequentially with water and ethanol. Thirdly, the 10 mg SiO2@Fe3O4 NPs was re-dispersed into 10 mL ethanol, and 500 μL of APTMS was added and stirred for 24 h under N2 protection at room temperature to introduce amino-silane coating of SiO2@Fe3O4 NPs. Finally, EDC-NHS coupling was used for the attachment of the Tat peptide to amino-functionalized NPs. The as-prepared 100 μL of amino-SiO2@Fe3O4 NPs (1 mg/mL) was activated using EDC (4 nmol) and NHS (4 nmol). Then, 10 μL of FITC-Tat peptide (1 mg/mL) was added to the mixture and stirred for 3 h under N2 protection at room temperature to obtain the final Tat-conjugated SiO2@Fe3O4 NPs (Tat-SiO2@Fe3O4 NPs) which were lyophilized for further observation after centrifugation and washing with water.

Characterizations of Nanoparticles

The morphology of synthesized nanoparticles was characterized under a Philips JEM-2100HC transmission electron microscope (TEM) with an accelerating voltage of 150 kV. X-ray powder diffraction (XRD) patterns were recorded on an X’Pert-Pro diffractometer (PANalytical, Holland) in the 2q range from 20° to 80°. Element analysis was carried on a PHI-Quantum 2000 X-ray photoelectron spectroscopy (Physical Electronics, Inc, Japan). The hydrodynamic diameter and zeta potential of the as-synthesized NPs were measured on a Nano-ZS Zetasizer dynamic light scattering (DLS) detector (Malvern Instruments, UK), and the results were analyzed using the Malvern Zetasizer software assuming a log normal distribution. The magnetic properties of the products were characterized by vibrating sample magnetometry (VSM) in an applied magnetic field sweeping from −18 to 18 kOe. The elemental composition of the nanoparticles was characterized by Quantum 2000 X-ray photoelectron spectroscopy (XPS, PHI, US). Fourier transform infrared spectroscopy (FTIR) spectra of the samples were recorded on Nicolet-APTMSVATAR360 spectrometer in the range 4000–400 cm−1 using the KBr-disk method. The thermo-gravimetric analysis (TGA) was taken at a heating rate of 10 °C min−1 in a nitrogen atmosphere with a Pyris Diamond TGA thermal analyzer (PerkinElmer, Massachusetts, USA).

Additionally, iron content in nanoparticles or cell samples was determined by a colorimetric assay based on chromogenic reaction of Fe(III) with potassium thiocyanate. For a typical sample, 0.1 mL suspension was successively incubated with sodium hydroxide (0.1 mL, 5 mol/L) for 1 h at 80 °C, concentrated hydrochloric acid (0.1 mL, 12 mol/L) for 2 h at 55 °C, and excess ammonium persulfate (100 μg/mL) for 15 min at room temperature to remove SiO2 coating and oxidize Fe element in samples into Fe(III). After 10 min incubation of Fe(III) with potassium thiocyanate (0.1 mol/L), a red complex iron-thiocyanate form and the absorbance were detected using UV-vis spectrophotometer at the wavelength of 478 nm. Serial Fe(III) dilutions in the range 0–80 μg/mL were prepared to obtain a standard. Then, Fe content in sample is calculated as the absorbance from a standard curve. In the following experiments, amount of NPs was directly accounted as content.

Construction and Characterization of BBB Models

To construct the BBB models, hCMEC cells were seeded on uncoated PET membrane of Transwell filter insides (1 μm pore size) in 500 μL medium at 1 × 105 cells/well. Cells were cultured with the RPMI 1640 medium at 37 °C and in 5 % CO2, and the medium was changed every 2 days. After 7–10 days, a confluent hCMEC monolayer was generated. U251 cell monolayer was selected as the control.

For the characterization of the BBB model, the cell morphology of monolayer was initially observed by phase contrast optical microscopy. Immune-staining of tight junction-associated protein ZO-1 was performed to determine the BBB tight junction. Briefly, the cell monolayer on Transwell inserts was clipped and washed with PBS and then fixed in 4 % paraformalclehyde for 30 min and blocked with 1 % BSA for further 30 min. After washing with PBS, a monoclonal rabbit anti-ZO-1 antibody (diluted 1/50 in 1 % BSA in PBS, 300 μL) was added and incubated for 30 min. Next, TRITC conjugated mouse anti-rabbit IgG (diluted 1/50 in 1 % BSA in PBS, 300 μL) was added and incubated for 1 h. After washing the cells, the samples were stained with Hoechst (10 μg/mL, 300 μL). The tightness of the cellular barrier is further assessed by transendothelial electrical resistance (TEER) of monolayer. Only the monolayers with TEER over 150 Ω were used for studies.

BBB permeability was estimated by examining the transport of disodium salt (Na-F) and horseradish peroxidase (HRP) through monolayers for various periods. Fluorescence microcopy was used to examine the amount of Na-F. Permeability coefficient (Pe) values of Na-F through BBB mode can be determined by the equation \( \frac{1}{P}=\frac{1}{Pt}-\frac{1}{Pf} \) where Pt and Pf correspond to the permeability coefficient values of Na-F through cell monolayer and control filter, respectively. HRP penetration of monolayers was examined as previously reported [31]. The experiment was repeated three times.


MTT assay was used to access in vitro cytotoxicity. The hCMEC cells were seeded into 96-well plate at 5 × 103 cells/well and incubated for 24 h till the 70 % confluence. Then, Fe3O4@SiO2-Tat or Fe3O4@SiO2-Amino NPs with different concentrations (100, 200, 400, 600, and 800 μg/mL) were added to each well. The untreated hCMEC cells were used as control. After another 24 h incubating, a standard MTT was carried out according to the instructions.

In Vitro Uptake Study Under Magnetic Field

The hCMEC cells were seeded in a 24-well plate at 2 × 105 cells/well and cultured overnight. The cells were treated with 100 μg of Fe3O4@SiO2-Amino or Fe3O4@SiO2-Tat NPs with external magnetic field placed with a magnet on cell plate for varied periods (0, 0.5, and 2). After incubation for a further periods (2 or 12 h), the cells were washed with PBS, then lysed. Total protein concentration was determined using the BCA protein assay kit. Uptake amounts of NPs were determined through measuring the element Fe.

BBB Transport Experiment

For quantifying BBB penetrating efficiency, the hCMEC monolayers with TEER value over 150 Ω cm2 were selected as the BBB model of hCMEC cells. Two hundred micrograms of Fe3O4@SiO2-Amino or Fe3O4@SiO2-Tat NPs was added into the apical chambers and incubated for 24 h. Then, each well was irradiated with external magnetic field for varied periods (0, 0.5, 2, and 8 h). RPMI 1640 medium was used as the blank control. After removing external magnetic field, the NPs were added and incubated for another 26 h. TEER of monolayer was detected in the interval of 1 h and a plot of the TEER—time curve was made. After washing with PBS, the hCMEC cells for each variable (NPs only, NPs + magnet and irradiation time) were lysed and transportation efficiency was assessed through determining the ratio of the element Fe in bottom chambers.

Penetrating Through a hCMEC Monolayer and Further Location in U251 Cells

For construction of co-culture BBB models, hCMEC cells were seeded on Transwell insides at a density of 1 × 105 cells and incubated for about 8 days to form a compact monolayer. Subsequently, U251 glioma cells were seed at the bottom of the Transwell at 1.5 × 105 cells/well and cultured for 24 h till the 70 % confluence. Until the resistance of hCMEC monolayer was examined over 150 Ω cm2, 200 μg of FITC-labeled Fe3O4@SiO2-Amino and Fe3O4@SiO2-Tat NPs was added to the apical chambers of the BBB models. Subsequently, each well was irradiated for 2 h under external magnetic field. After incubation for another 24 h, U251 cells on the bottom chambers were washed in PBS and harvested. To determine the penetration ability of NPs, the cells for each variable FITC-labeled NPs (NPs only and NPs + magnet) were collected and the penetrating ability was evaluated though quantifying the cellular uptake of the U251 cells with a flow cytometer (Beckman Coulter, USA). Additionally, confocal laser scanning microscope (CLSM) is also used for observation the internalization and location of FITC-labeled NPs. The cells for each variable FITC-labeled NPs (NPs only and NPs + magnet) were collected and fixed with paraformaldehyde (4 % in PBS) for 30 min. Then, cells were treated with Hoechst 33258 (10 mg/mL) for 20 min to stain the nucleus. An inverted CLSM (FluoviewFV1000, Olympus, Japan) equipped with a Plan-Apochromat 60 × 0.7 NA lens was used to observe the samples.

Statistical Analysis

Statistical analysis was conducted using a two-tailed unpaired Student’s t test. The results were presented as mean ± standard deviation.

Results and Discussion

Synthesis and Characterization of NPs

The strategy to prepare core-shell SiO2@Fe3O4-Tat NPs involves four steps, consisting of synthesis of Fe3O4 nanoparticles by co-precipitation, growth of a silica shell, surface amination, followed by conjugation of Tat peptide through EDC/NHS coupling reactions, as depicted in Scheme 1. Fe3O4 NPs were easily coated with a uniform SiO2 shell by the Stöber method [30]. TEM image in Fig. 1a revealed a spheroid and uniform morphology of the Fe3O4@SiO2 NP. An approximately 20 nm of black central portion of the probe is the magnetic nucleus with a larger electron density, and the surrounding gray portion of 4 nm thick is the amorphous SiO2 wrap. XRD patterns of the Fe3O4, Fe3O4@SiO2 NPs, and Fe3O4@SiO2-Amino NPs are shown in Fig. 1b. Six diffraction peaks at 2θ = 30.4, 35.7, 43.4, 53.7, 57.4, and 62.7 corresponded to the (220), (311), (400), (422), (511), and (440) planes of the inverse cubic spinel structure of Fe3O4, respectively (JCPDS card no. 09-0432). The presence of a broader peak at 2θ = 23 illustrated the amorphous silica coating on Fe3O4 NPs. No evident differences were observed for Fe3O4@SiO2 and Fe3O4@SiO2-Amino NPs, suggesting that amino modification of Fe3O4 NPs did not lead to any crystal phase change.
Fig. 1
Fig. 1

a TEM images of Fe3O4@SiO2 NPs; b the X-ray diffraction patterns; and c the FTIR spectra of Fe3O4, Fe3O4@SiO2, and Fe3O4@SiO2-Amino NPs

Successive introduction of amino group was confirmed by FTIR analyses. FTIR spectra of the Fe3O4, Fe3O4@SiO2, and Fe3O4@SiO2-Amino NPs were examined and shown in Fig. 1c. The characteristic bands at 582 cm−1 corresponded to the vibration of the Fe–O bonds. The bands at 1617 and 1401 cm−1 were assigned to the stretching vibrations of carboxyl salt, suggesting the presence of coordinative effect in the Fe (III)-carboxylate group [32]. The characteristic absorption bands at 1096, 799, and 467 cm−1 for Si–O–Si group confirmed that the Fe3O4 NPs were encapsulated by a layer of silica. The IR spectrum of Fe3O4@SiO2-Amino NPs showed that the weak bands at 1549 cm−1 belonged to the bending vibration of amine group and two broad bands at 2984 and 2927 cm−1 corresponded to C–H stretching vibration. The presence of a band at 798 cm−1 may be attributed to the Si–C stretching vibrations, indicating the conjugation of amide groups with the silica framework via the APTES hydrolysis [33]. Moreover, the XPS was used to explore the elemental compositions of functional Fe3O4 NPs. As shown in Fig. 2, the Fe 2p and Si 2p XPS patterns appeared on spectrum of bare Fe3O4 and Fe3O4@SiO2 NPs, respectively, which can be assigned to SiO2 coating. The N1s binding energy peak at 397.5 eV only was presented in XPS spectrum of Fe3O4@SiO2-Amino NPs, suggesting successful APTES conjugation. It is also found that a peak at 284.9 eV on total scan spectra can be assigned to C–C bonds of citrate ions [33].
Fig. 2
Fig. 2

a XPS survey scan spectra; b Fe2p, c Si2p, and d N1s of Fe3O4, Fe3O4@SiO2, and Fe3O4@SiO2-Amino NPs

Peptide Tat was covalently immobilized onto activated magnetic nanoparticles with EDC/NHS as shown in Scheme 1. FITC-labeled Tat peptide was used in the synthesis process to confirm the conjugation of Tat peptide. An obvious absorbance at 520 nm in the fluorescence spectrum of Fe3O4@SiO2-Tat NPs indicated the successfully conjugation of Tat peptide on the surface (Fig. 3a). TGA was used to quantitatively characterize the modification efficiency of Tat peptide onto the surface of Fe3O4@SiO2 NPs. TGA curves of Fe3O4@SiO2-Tat NPs in Fig. 3b showed three transitions during the temperature of (i) 25–100 °C, (ii) 100–230 °C, and (iii) 230–550 °C. The first weight loss of 2.51 % was associated to the surface water removal, the second one (1.73 %) indicated the decomposition of Tat peptide, while the last section (3.30 %) corresponded to the thermal decomposition of grafted APTES. No further weight loss occurred with the increase of temperature and total organic matters of Fe3O4@SiO2-Tat NP weighted for 5.03 %.
Fig. 3
Fig. 3

a The fluorescence spectra of Fe3O4@SiO2-Amino and Fe3O4@SiO2-Tat NPs. b The TG and DTG curves of Fe3O4@SiO2-Tat NPs

Surface modification changes the particle size and surface charge but also influences the uptake ability and pathway of NPs into the cells. As shown in Table 1, hydrodynamic size of Fe3O4, Fe3O4@SiO2, and Fe3O4@SiO2-Amino and Fe3O4@SiO2-Tat NPs (23.7, −72.8, 76.4, and 87.6 nm, respectively) gradually increased along with the functionalization procedure. The larger hydrodynamic sizes than TEM values may be due that DLS measures large aggregates in aqueous solution while TEM just measures single Fe3O4 NP. On the other hand, Fe3O4@SiO2 NPs showed less negative charges (−15.4 mV) than that of bare Fe3O4 NPs (−23.7 mV) due to the shielding effect of silica coating on citrate ions. And, the remaining negativity might be attributed to the existence of a large amount of silanol groups on surface. After surface amination of APTES, the zeta potential of Fe3O4@SiO2-Amino NPs become toward positive position (24.9 mV) due to the introduction of amino. After further conjugating with cationic peptide Tat, the averaged zeta potential was 42.1 mV, which was beneficial to efficient entrapment of negative cell delivery.
Table 1

Zeta potential and particle size


Zeta potential (mV)

Size (nm)


−23.7 ± 1.87

23.7 ± 2.06


−15.4 ± 1.05

72.8 ± 2.54


24.9 ± 2.05

76.4 ± 1.27


42.1 ± 2.25

87.6 ± 3.23

Finally, the magnetic properties of the three types of modified MNPs mentioned above were measured by VSM at room temperature. No remnant magnetization and hysteresis were shown in Fig. 4, suggesting their superparamagnetic property. The saturation magnetization (Ms) of Fe3O4@SiO2, Fe3O4@SiO2-Amino, and Fe3O4@SiO2-Tat NPs were 27.4, 22.1, and 19.21 emu g−1, respectively. The gradual decrease in Ms is due to an increase in the thickness of Fe3O4 coating along with the functionalization procedure. And, magnetic response of Fe3O4@SiO2-Tat NPs was large enough to quickly separate particles from solution by the magnet (Fig. 4, inset). This property could endow Fe3O4@SiO2-Tat NPs with magnetically mediated tumor targeting.
Fig. 4
Fig. 4

Normalized magnetization curves of Fe3O4@SiO2, Fe3O4@SiO2-Amino, and Fe3O4@SiO2-Tat NPs

Characterization of the BBB Model

The confluent hCMEC monolayers were used to prepare in vitro BBB model which can be assessed through some indicators such as morphological, tight junction protein staining, TEER value measurements, and permeability studies.

As shown in Fig. 5a, on day 8 of culture, the confluent hCMEC cells form a monolayer without aperture as it was seen on a phase contrast optical microscopy. The high expression of zonula occludens was the characteristic of the confluent brain endothelial cell monolayers. An immune-staining of the endothelial specific tight junction protein ZO1 (Fig. 5b, c) revealed an increasing amount of punctuated fluorescence at intracellular regions along with the growth of cells, which confirmed that the tight junctions had been correctly assembled.
Fig. 5
Fig. 5

a Images of BBB model at the eighth day; immune-staining of tight joint—ZO-1 for hCMEC monolayer (b) and U251 control (c) at the eighth day; d The permeability of HRP. e TEER measurement on the hCMEC monolayer, U251 monolayer, and PET membrane control. Bar: 50 μm

BBB integrity was evaluated using Na-F and HRP exogenous tracers [34]. PS values of Na-F were calculated to be 1.66 and 23.84 × 10−3 cm/min for hCMEC and U251 cells, respectively (data not shown), in accordance with previously published data [35]. The permeability of HRP on BBB is only 1.05 % within 10 h, while up to 50 % of HRP had transfer across monolayer of U251 cells and the value increased with longing time (Fig. 5d). The low permeability of hCMEC monolayer meant a strong restriction for small hydrophilic molecules and macromolecule tracers, illustrating the tightening of BBB model.

The TEER is commonly used to assess the integrity of brain endothelial cell monolayer. Previous studies indicated that over 120 Ω × cm2 of TEER value can account for the in vitro BBB integrity [36]. In our model, a higher TEER value above 150 Ω × cm2 was monitored on 8 days and it will not change evidently in the next week (Fig. 5e), suggesting the confluent monolayer could be used as an in vitro model for exploring the NPs transport.

In Vitro Cytotoxicity

The cytotoxicity of NPs remains a matter of concern in their application as drug carrier. MTT assay was commonly used to determine the cytotoxicity in a concentration-dependent manner. As shown in Fig. 6, Fe3O4@SiO2-Tat and Fe3O4@SiO2-Amino NPs maintained above 70 % of the cell viability in the tested concentrations, and the cytotoxicity appeared in dose-dependent manner. Besides, Tat-conjugated NPs showed a slight decrease of cell viability relative to Fe3O4@SiO2-Amino NPs, due to a reduced membrane trans-locating activity from Tat [37]. During the tested concentrations below 800 mg/mL, the NPs were non-cytotoxic.
Fig. 6
Fig. 6

Normalized dose–response for cell viability of Fe3O4@SiO2-Amino and Fe3O4@SiO2-Tat NPs by MTT assay

In Vitro Uptake Study Under Magnetic Field

To evaluate the possibility of NPs across the BBB, we first determined whether Fe3O4@SiO2-Tat NPs can be internalized into brain endothelial cells in the present or absent of magnetic field. Flow cytometry experiments were used to quantity the internalization of the Tat-conjugated and non-conjugated NPs inside the cells.

The different cell uptake percentage has been displayed in Fig. 7, as a result of the differently grafted group and explosion time to magnetic field. When a magnetic force was exerted for 0.5 or 2 h, cell internalization had been shown to increase by 1.8/2.6 times for Fe3O4@SiO2-Tat NPs and 1.5/3.5 times for Fe3O4@SiO2-Amino NPs, respectively. The result suggested a magnet aid endocytosis process. Moreover, the cellular uptake of both NPs by hCMEC cells was increased by two to three times with incubation time prolonging from 2 to 12 h, indicating a time-dependent cellular internalization. Besides, it has also been found that conjugation with peptide Tat could enhance by 1.2–2.2 times cellular uptake on varied explosion time (0–2 h) relative to Fe3O4@SiO2-Amino NPs, suggesting that Tat peptide could increase internalization efficiency of NPs into brain capillary endothelial cells by Tat-mediated membrane destabilization.
Fig. 7
Fig. 7

The effect of external magnetic field (permanent magnet) on the uptake of magnetic nanoparticles by hCMEC cells

Passage of NPs Through BBB

A major problem of targeting the brain lies in the poor BBB penetration. Therefore, the transport of NPs over the BBB is a critical issue. In our experiment, NPs were added in the apical chamber of in vitro BBB model. If transcytosis of NPs occurs, they will transfer across the filters of Transwell and then be found in the bottom chamber. By analyzing the ratio of trans-cellular nanoparticles to adding amount, we can rank their transport efficiencies.

It is indicated from Fig. 8 that both NPs are able to effectively cross over BBB in the absence of magnetic field. And, transport efficiencies were increased with exposure time of magnetic field longing. Fe3O4@SiO2-Amino increased 17 % passage ratio after applying a magnetic force for 8 h, while Fe3O4@SiO2-Tat NPs was enhanced 1.8-, 2.3-, and 2.8-fold at the exposure periods of 0.5, 2, and 8 h, respectively, compared with that without external magnetic force. This result indicated a magnetic field-increased permeability of NPs across hCMEC monolayer. Under the same magnetic conditions, Tat-conjugated Fe3O4@SiO2-Amino induced greater passage ratio than non-conjugated ones. The increase could result from an enhanced recognition and affinity to the cells which sequentially triggered receptor-mediated endocytosis and increased accumulation of nanoparticles in cells and the transportation [38]. It also was reported that some PIONs covered by biomolecules accumulated at a higher concentration in the tumors when they were subjected to an external magnetic field [27]. Hence, our prepared Fe3O4@SiO2-Tat NPs have the potential to be magnetically mediated brain-targeting carrier.
Fig. 8
Fig. 8

Transport efficiency of Fe3O4@SiO2-Tat and Fe3O4@SiO2-Amino NPs

The effect of NPs across BBB was further evaluated by monitoring the changes of the TEER before and after the existence of NPs under the external magnetic field. As shown in Fig. 9, the TEER values exhibited a similar variation tendency, declining at 2 h incubation, and reaching to the minimum at 8 h, then gradually recovering and basically reaching more than 75 % of the initial value at 26 h. This observation in good agreement with the previous report [39] may be due to the fluctuations of cell monolayer when introduction of extracellular matters. Besides, the reduction of TEER values increased with exposure time longing, and it is inversely to recovery rate. NPs passage and accumulation did not harm the integrity of in vitro BBB model.
Fig. 9
Fig. 9

Normalized TEER values of BBB model recorded after the introduction of nanoparticles with magnetic explosion periods. a Fe3O4@SiO2-Amino NPs (F). b Fe3O4@SiO2-Tat NPs (FT)

Uptake and Location in U251

For an efficient brain-targeting therapy, the internalization and accumulation of carriers in brain cells are also important. To mimic a more realistic in vivo situation, U251/hCMEC co-culture BBB model was built and used to investigate uptake and location of nanoparticles in U251 cells in the bottom chamber. As shown in Fig. 10, Fe3O4@SiO2-Tat and Fe3O4@SiO2-Amino NPs, respectively, increased 17.4- and 19.0-fold uptake by U251 cells after 2 h explosion of magnetic field, compared with no-magnet groups of 4.27 and 5.19 %. The result suggested the application of external magnetic field greatly facilitated NPs internalization into the cells within the brain. Moreover, the internalization of Fe3O4@SiO2-Tat was higher than that of Fe3O4@SiO2-amino NPs whether or not to apply a magnetic field, further reflecting trans-membrane effect of Tat peptide.
Fig. 10
Fig. 10

Flow cytometry of U251 cells containing NPs. a Control group; Fe3O4@SiO2-Amino NPs, b in the absence of magnetic field, and c under magnetic explosion for 2 h; Fe3O4@SiO2-Tat NPs, d in the absence of magnetic field and e under magnetic explosion for 2 h. Higher intensity along the x axis indicates more FACS delivery, and percentage of cells with internalized NPs is indicated

For detecting the ultimate fate of NPs after passage over BBB, FITC-labeled NPs was used as an optical probe, and their intracellular localization in U251 cells were analyze by CLSM after 2 h explosion of magnetic field. As shown in Fig. 11, much more green dots of Fe3O4@SiO2-Tat distributed within cytoplasm compared with non-conjugated ones, consistently in FCM results. Moreover, the merged yellow fluorescent dots demonstrated that almost of Tat-conjugated Fe3O4@SiO2-Amino NPs accumulated in nucleus zone, indicating that Fe3O4@SiO2-Tat NPs can enter into cell nucleus. In contrast, no green dots of Fe3O4@SiO2-Amino NPs were detected in the blue nucleus district. It has been reported that partly Tat-grafted nanoparticles can be cross over nuclear membrane [40, 41]. Our findings may suggest that a synergy effect of magnetic force and Tat peptide can enhance cell internalization and nucleus targeting.
Fig. 11
Fig. 11

The localization of nanoparticles in U251 cells. ac Fe3O4@SiO2-Amino NPs. df Fe3O4@SiO2-Tat NPs


To sum up, Tat-conjugated SiO2@Fe3O4 NPs exhibited suitable magnetism and good biocompatibility. The functionalization with Tat peptide facilitated particles to pass through in vitro BBB and enter into the nucleus of U251 glioma cells co-cultured at the bottom chamber. Moreover, the synergistic effects of Tat and magnetic field could promote the cell uptake of hCMEC cells and entry to nuclear of U251, hence efficiently enhancing permeability across BBB and subsequent accumulation in glioma cells. It also found that Fe3O4@SiO2-Tat NPs can be transported through the in vitro BBB via a trans-cellular trafficking mechanism and magnetically mediated dragging. Therefore, SiO2@Fe3O4-Tat NPs could be exploited as a potential brain-targeting carrier for diagnosis and treatment of the brain disease.



The authors would like to appreciate the support from the National Natural Science Foundation of China (No. 31371012, 31428007, U1505228, 31400797) and Founds of Science Technology Department of Zhejiang Province (No. 2015C37031).


This study was financially supported by the National Natural Science Foundation of China (No. 31371012, 31428007, U1505228, 31400797) and Founds of Science Technology Department of Zhejiang Province (No. 2015C37031).

Authors’ Contributions

ZX and ST performed the experiments and prepared the manuscript. YT participated in the construction of BBB model. ZX and WD participated in the synthesis and characterization of nanoparticles. ZX and RL supervised the whole work and revised the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, 310018, People’s Republic of China
Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, People’s Republic of China


  1. Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19(12):1584–1596View ArticleGoogle Scholar
  2. Jiang X (2013) Brain drug delivery systems. Pharm Res-Dordr 30(10):2427–2428View ArticleGoogle Scholar
  3. Clark AJ, Davis ME (2015) Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci U S A 112(40):12486–12491View ArticleGoogle Scholar
  4. Nomura T, Nishimura Y, Gotoh H, Ono K (2016) Rapid and efficient gene delivery into the adult mouse brain via focal electroporation. Sci Rep 6:29817View ArticleGoogle Scholar
  5. Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA (2016) The effect of regadenoson-induced transient disruption of the blood–brain barrier on temozolomide delivery to normal rat brain. J Neurooncol 126(3):433–439View ArticleGoogle Scholar
  6. Mason WP (2015) Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma. Neuro Oncol 17(9):1181–1812Google Scholar
  7. Trippier PC (2016) Properties to optimize small molecule blood-brain barrier penetration. Curr Med Chem 23(14):1392–1407View ArticleGoogle Scholar
  8. Lajoie JM, Shusta EV (2015) Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol 55(1):613–631View ArticleGoogle Scholar
  9. Mo J, He L, Ma B, Chen T (2016) Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood-brain barrier. ACS Appl Mater Inter 8(11):6811–6825View ArticleGoogle Scholar
  10. Mangraviti A, Gullotti D, Tyler B, Brem H (2016) Nanobiotechnology-based delivery strategies: new frontiers in brain tumor targeted therapies. J Control Release. doi:10.1016/j.jconrel.2016.03.031 Google Scholar
  11. Zhao X, Wang J, Tao S, Ye T, Kong X, Ren L (2016) In vivo bio-distribution and efficient tumor targeting of gelatin/silica nanoparticles for gene delivery. Nanoscale Res Lett 11(1):1–9View ArticleGoogle Scholar
  12. Estelrich J, Escribano E, Queralt J, Busquets MA (2015) Iron Oxide Nanoparticles for Magnetically-Guided and Magnetically-Responsive Drug Delivery. Int J Mol Sci 16(4):8070–8101View ArticleGoogle Scholar
  13. Orlando A, Colombo M, Prosperi D, Gregori M, Panariti A, Rivolta I, Masserini M, Cazzaniga E (2015) Iron oxide nanoparticles surface coating and cell uptake affect biocompatibility and inflammatory responses of endothelial cells and macrophages. J Nanopart Res 17(9):1–13View ArticleGoogle Scholar
  14. Huang Y, Zhang B, Xie S, Yang B, Xu Q, Tan J (2016) Superparamagnetic iron oxide nanoparticles modified with Tween 80 pass through the intact blood-brain barrier in rats under magnetic field. ACS Appl Mater Inter 8(18):11336–11341View ArticleGoogle Scholar
  15. Dan M, Bae Y, Pittman TA, Yokel RA (2015) Alternating magnetic field-induced hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood–brain barrier models. Pharm Res-Dordr 32(5):1615–1625View ArticleGoogle Scholar
  16. Gräfe C, Weidner A, Lühe MV, Bergemann C, Schacher FH, Clement JH, Dutz S (2016) Intentional formation of a protein corona on nanoparticles: serum concentration affects protein corona mass, surface charge, and nanoparticle–cell interaction. Int J Biochem Cell Biol 75:196–202View ArticleGoogle Scholar
  17. Kiliç G, Costa C, Fernández-Bertólez N, Pásaro E, Teixeira JP, Laffon B, Valdiglesias V (2016) In vitro toxicity evaluation of silica-coated iron oxide nanoparticles in human SHSY5Y neuronal cells. Toxicol Res-UK 5(1):235–247View ArticleGoogle Scholar
  18. Tang Y, Zhang C, Wang J, Lin X, Zhang L, Yang Y, Wang Y, Zhang Z, Bulte J, Yang GY (2015) MRI/SPECT/fluorescent tri-modal probe for evaluating the homing and therapeutic efficacy of transplanted mesenchymal stem cells in a rat ischemic stroke model. Adv Funct Mater 25(7):1024–1034View ArticleGoogle Scholar
  19. Arami H, Khandhar A, Liggitt D, Krishnan KM (2015) In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev 44(23):8576–8607View ArticleGoogle Scholar
  20. Richard S, Boucher M, Herbet A, Lalatonne Y, Mériaux S, Boquet D, Motte L (2015) Endothelin B receptors targeted by iron oxide nanoparticles functionalized with a specific antibody: toward immunoimaging of brain tumors. J Mater Chem B 3(15):2939–2942View ArticleGoogle Scholar
  21. Komin A, Russell LM, Hristova KA, Searson PC (2016) Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: mechanisms and challenges. Adv Drug Deliv Rev, doi: 10.1016/j.addr.2016.06.002
  22. Zhang D, Wang J, Xu D (2016) Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release 229:130–139View ArticleGoogle Scholar
  23. Cai Q, Wang L, Deng G, Liu J, Chen Q, Chen Z (2016) Systemic delivery to central nervous system by engineered PLGA nanoparticles. Am J Transl Res 8(2):749–764Google Scholar
  24. Goswami D, Vitorino HA, Alta RY, Silvestre DM, Nomura CS, Machini MT, Espósito BP (2015) Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine. BioMetals 28(5):869–877View ArticleGoogle Scholar
  25. Xu R, Feng X, Xie X, Zhang J, Wu D, Xu L (2012) HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9. Brain Res 1436:13–19View ArticleGoogle Scholar
  26. Kanazawa T, Morisaki K, Suzuki S, Takashima Y (2014) Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles. Mol Pharm 11(5):1471–1478View ArticleGoogle Scholar
  27. Thomsen LB, Linemann T, Pondman KM, Lichota J, Kim KS, Pieters RJ, Visser GM, Moos T (2013) Uptake and transport of superparamagnetic iron oxide nanoparticles through human brain capillary endothelial cells. ACS Chem Neurosci 4(10):1352–1360View ArticleGoogle Scholar
  28. Bicker J, Alves G, Fortuna A, Falcão A (2014) Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur J Pharm Biopharm 87(3):409–432View ArticleGoogle Scholar
  29. Jitianu A, Raileanu M, Crisan M, Predoi D, Jitianu M, Stanciu L, Zaharescu M (2006) Fe3O4–SiO2 nanocomposites obtained via alkoxide and colloidal route. J Sol-Gel Sci Technol 40(2):317–323View ArticleGoogle Scholar
  30. Graf C, van Blaaderen A, Imhof A (2003) A general method to coat colloidal particles with silica. Langmuir 19(17):6693–6700View ArticleGoogle Scholar
  31. Xie Y, Ye L, Zhang X, Cui W, Lou J, Nagai T, Hou X (2005) Transport of nerve growth factor encapsulated into liposomes across the blood–brain barrier: In vitro and in vivo studies. J Control Release 105(1–2):106–119View ArticleGoogle Scholar
  32. Shen LH, Bao JF, Wang D, Wang YX, Chen ZW, Ren L, Zhou X, Ke X, Chen M, Yang AQ (2013) One-step synthesis of monodisperse, water-soluble ultra-small Fe3O4 nanoparticles for potential bio-application. Nanoscale 5(5):2133–2141View ArticleGoogle Scholar
  33. Viswanathan V, Murali G, Gandhi S, Kumaraswamy P, Sethuraman S, Krishnan UM (2014) Development of thioflavin-modified mesoporous silica framework for amyloid fishing. Micropor Mesopor Mat 197:40–47View ArticleGoogle Scholar
  34. Kaya M, Ahishali B (2011) Assessment of permeability in barrier type of endothelium in brain using tracers: Evans blue, sodium fluorescein, and horseradish peroxidase. In: Turksen K (ed) Permeability barrier: methods and protocols. Humana Press, Totowa, pp 369–382View ArticleGoogle Scholar
  35. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, Tanaka K, Niwa M (2009) A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54(3–4):253–263View ArticleGoogle Scholar
  36. Kang T, Jiang M, Jiang D, Feng X, Yao J, Song Q, Chen H, Gao X, Chen J (2015) Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm 12(8):2947–2961View ArticleGoogle Scholar
  37. Vivès E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272(25):16010–16017View ArticleGoogle Scholar
  38. Liu L, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC, Ling EA, Moochhala S, Yang YY (2008) Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG–TAT for drug delivery across the blood–brain barrier. Biomaterials 29(10):1509–1517View ArticleGoogle Scholar
  39. Varga N, Csapó E, Majláth Z, Ilisz I, Krizbai IA, Wilhelm I, Knapp L, Toldi J, Vécsei L, Dékány I (2016) Targeting of the kynurenic acid across the blood–brain barrier by core-shell nanoparticles. Eur J Pharm Sci 86:67–74View ArticleGoogle Scholar
  40. Tammam SN, Azzazy HME, Lamprecht A (2016) How successful is nuclear targeting by nanocarriers? J Control Release 229:140–153View ArticleGoogle Scholar
  41. Peng LH, Niu J, Zhang CZ, Yu W, Wu JH, Shan YH, Wang XR, Shen YQ, Mao ZW, Liang WQ, Gao JQ (2014) TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells. Biomaterials 35(21):5605–5618View ArticleGoogle Scholar


© The Author(s). 2016